SUGAR INTAKE AND CARDIOVASCULAR DISEASE - SHOULD IT BE THE NEXT FIGHT TO DECREASE CVD?
EAS Academy, Jean-Pierre Despres, 136678
SHOULD SATURATED FAT BE TARGETED FOR THE PREVENTION OF CARDIOVASCULAR DISEASE?
EAS Academy, Alice H. Lichtenstein, 136677
Swedish experience from patient society
EAS Academy, Gunnar Karlsson, 118047
The lipid clinic and organization of FH, the role of different participants in the team
EAS Academy, Kjetil Retterstøl, 118046
FH in children
EAS Academy, Albert Wiegman, 118044
The role of new lipid lowering drugs
EAS Academy, Kausik Ray, 118043
Treatment of FH: Diet, statin and statin intolerance
EAS Academy, Olov Wiklund, 118042
Cascade screening introduction and experience from Czech Republic
EAS Academy, Tomas Freiberger, 118039
Cascade screening introduction and experience from Spain
EAS Academy, Pedro Mata, 118040
Diagnosis of FH: Scoring systems and Genetic diagnosis, Polygenic causes of clinical FH
EAS Academy, Joep Defesche, 118038
Genetics of FH mutation and distribution
EAS Academy, Stefano Romeo, 118037
The population burden of FH- The need to close the gap
EAS Academy, Kausik Ray, 118036
Certificate of Education in Familial Hypercholesterolaemia
EAS Academy, EAS, 113072
Case based approach to Familial Hypercholesterolemia
EAS Academy, EAS, 113071
EAS Training Programme in Lipidology
EAS Academy, EAS, 99063
Personal Information
EAS Academy, EAS, 99259
Personal Information
EAS Academy, EAS, 113067
Module 5: Mendelian randomization approach to understand effect of lipoprotein in causing disease
EAS Academy, Anne Tybjaerg-Hansen, 99034
Investing in your arteries: lifetime management of CVD risk
EAS Academy, John E. Deanfield, 97705
Concluding remarks
EAS Academy, Kausik Ray, 98851
Taking a quantum leap in management strategies
EAS Academy, Seth Baum, 97693
The therapeutic backbone
EAS Academy, Claudia Stefanutti, 97692
Modernising our understanding of HoFH
EAS Academy, Jeanine Roeters van Lennep, 97691
What is the best lipid treatment target? Discussion from the diversity of current guidelines.
EAS Academy, Alberico L. Catapano, 97687
What is the role of the different lipoproteins in atherogenesis?
EAS Academy, Jan Borén, 97686
Imaging for estimation risk and disease regression, advancements and new techniques.
EAS Academy, Zahi Fayad, 97685
Future therapies
EAS Academy, Erik Stroes, 97682
Current status of hypolipidaemic therapies
EAS Academy, Chris Packard, 97681
Dyslipidaemias: from lifestyle to genetics
EAS Academy, Kausik Ray, 97680
Engaging with governments- how to get genetic screening into law
EAS Academy, Mario Stoll, 97676
Getting started in your region and Data collation and National governance
EAS Academy, Kausik Ray, 97674
What worked well with the Dutch Database and what we are doing differently for the HoFH database
EAS Academy, Kees Hovingh, 97672
The Ten Countries Study - What's happening in the Asia Pacific Region and synergy with the FHSC
EAS Academy, Gerald Watts, 97671
The potential and limitations of historical data- using UK as an exemplar
EAS Academy, Handrean Soran, 97670
FH Studies Collaboration Symposium and Aims and objectives of the EAS FHSC and the FHSC survey
EAS Academy, Kausik Ray, 97668
EAS Advanced Course Attendance Certificate Upload 1 (mandatory)
EAS Academy, EAS, 98397
EAS Advanced Course or Congress Attendance Certificate Upload 2
EAS Academy, EAS, 98398
What genes can teach about the link between obesity and cardiometabolic traitan integrated approach
EAS Academy, Ruth Loos, 65108
Mendelian randomization: from genetic association to disease mechanism
EAS Academy, Anne Tybjaerg-Hansen, 65107
Genome wide association studies to find genetic determinants of cardiovascular disease
EAS Academy, Olle Melander, 65106
Discussion and data presentation on ANGPTL4
EAS Academy, Stefano Romeo, 65105
Tools to study candidate genes (2)
EAS Academy, Maria Antonella Burza, 65102
ANGPTL3 association and fasting triglycerides
EAS Academy, Stefano Romeo, 65101
Tools to study candidate gene (1)
EAS Academy, Maria Antonella Burza, 65100
Monogenic form of hypercholesterolemia
EAS Academy, Knut Erik Berge, 65097
Module 7: Genetics in cardiovascular disease
EAS Academy, EAS, 65167
Module 11: Pharmacological treatment of other dyslipidemias
EAS Academy, EAS, 65172
EAS Certificate of Excellence in Clinical Lipidology
EAS Academy, EAS, 65181
Consensus papers
EAS Academy, EAS, 113068
Epidemiological and clinical evidence in favour or against clinical utility of different procedures
EAS Academy, Dan O'Leary, 56082
Novel methods
EAS Academy, Erik Stroes, 56083
Classical and Novel Risk Factors
EAS Academy, Naveed Sattar, 56078
PCSK9 INHIBITION
EAS Academy, Bertrand Cariou, 56081
Rebuttal
EAS Academy, Luis Masana, 56099
Rebuttal
EAS Academy, Kausik Ray, 56098
All statins cause diabetes? The case AGAINST the motion
EAS Academy, Luis Masana, 56097
All statins cause diabetes? The case FOR the motion
EAS Academy, Kausik Ray, 56096
From nutrients to food: key features of our diet providing cardio prevention
EAS Academy, Frank Hu, 56073
Lessons from the PREDIMED trial
EAS Academy, Emilio Ros, 56074
Lessons from LOOK AHEAD
EAS Academy, Jean-Pierre Despres, 56075
Physical Activity and CVD risk
EAS Academy, Rainer Rauramaa, 56076
Monoclonal antibodies targeting PCSK9: gaining insight into their potential in clinical practice
EAS Academy, Alberico L. Catapano, 56778
Monoclonal antibodies targeting PCSK9: gaining insight into their potential in clinical practice
EAS Academy, Evan A. Stein, 56779
Management in Hyperlipidemia: what does the furture hold?
EAS Academy, Evan A. Stein, 56777
Hyperlipidemia management in high-risk patients: what we have and what we need
EAS Academy, John J.P. Kastelein, 56776
Diabetic Dyslipidemia
EAS Academy, Marja-Riitta Taskinen, 56067
REGULATION OF ADIPOGENESIS
EAS Academy, Ulf Smith, 56068
Lipotoxic heart disease
EAS Academy, Ira Goldberg, 56070
Review of current status for the guidelines on dyslipidemia – comparing European and US guidelines
EAS Academy, Olov Wiklund, 56063
Risk estimation and risk calculation
EAS Academy, Ian Graham, 56064
Challenges for future Guidelines
EAS Academy, Guy de Backer, 56065
Looking to the future – guidance on lipids and other targets
EAS Academy, Borge Nordestgaard, 56066
Mixed hyperlipidemia and triglycerides in current guidelines for treatment
EAS Academy, Olov Wiklund, 56061
Mechanistic bases for the origin and therapy of elevated triglycerides and mixed hyperlipidemia.
EAS Academy, Gerald Watts, 56060
Triglycerides, cholesterol and HDL in CVD – lessons from genetics
EAS Academy, Borge Nordestgaard, 56059
Role of Microbiota in Atherosclerosis
EAS Academy, Fredrik Bäckhed, 56051
Vaccination against atherosclerosis
EAS Academy, Johan Kuiper, 56053
Anitschkow Lecture
EAS Academy, John J.P. Kastelein, 56050
Tools of the trade - New treatment options in HoFH
EAS Academy, Dirk Blom, 56093
When to intervene - The urgency to treat
EAS Academy, Gilbert Thompson, 56092
Identifying the target - Who are we treating and to what target?
EAS Academy, Marina M. Cuchel, 56091
Diet – the corner stone of cholesterol management
EAS Academy, David Jenkins, 56043
Behaviour change is possible \'small steps – big difference\'
EAS Academy, Luis Masana, 56044
Behaviour change is possible, behaviour change in practice
EAS Academy, Helena Gylling, 56045
Introducing the e-Learning tool
EAS Academy, Simon Hackett, 56046
New advances in the role of Lp(a) in atherosclerosis; Therapeutic implications
EAS Academy, Olov Wiklund, 53306
Familial hypercholesterolemia: can we do a better job? Molecular genetics: is the screening of lipid disorders useful in clinical practice?
EAS Academy, Sebastiano Calandra, 53305
New therapeutic approaches in lipidology
EAS Academy, Alberico L. Catapano, 53304
Update on new EAS/ESC joint European guidelines for the prevention and treatment of dyslipidemia
EAS Academy, Alberico L. Catapano, 53302
CV risk evaluation through algorithms
EAS Academy, Olov Wiklund, 53301
Atherosclerosis: update on the pathophysiology: role of LDL
EAS Academy, Petri Kovanen, 53299
Emerging cardiovascular therapies targeting the immune system
EAS Academy, Jan Nilsson, 34718
Circulating Cells and Cardiovascular Risk
EAS Academy, Harry Björkbacka, 34712
Exploration and modulation of regulatory T cells in atherosclerosis
EAS Academy, Hafid Ait-Oufella, 34717
Immunomodulation of atherosclerosis
EAS Academy, Daniel F.J. Ketelhuth, 34716
The role of Dendritic Cells in Atherosclerosis
EAS Academy, Clément Cochain, 34713
T cell subsets in atherosclerosis
EAS Academy, Maria Wigren, 34835
Ontogeny and atherosclerosis pathology of B lymphocytes
EAS Academy, Stephen Malin, 34711
Emerging therapeutic approaches to treat dyslipidemias
EAS Academy, Chris Packard, 31157
Lipidomics ? a novel tool for biomarker discovery
EAS Academy, Robert Gerszten, 31155

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings